"Anti-Obesity Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
| Descriptor ID |
D019440
|
| MeSH Number(s) |
D27.505.954.427.140
|
| Concept/Terms |
Anti-Obesity Agents- Anti-Obesity Agents
- Agents, Anti-Obesity
- Anti Obesity Agents
- Anti-Obesity Drugs
- Anti Obesity Drugs
- Drugs, Anti-Obesity
- Antiobesity Drugs
- Drugs, Antiobesity
- Antiobesity Agents
- Agents, Antiobesity
Weight-Loss Agents- Weight-Loss Agents
- Agents, Weight-Loss
- Weight Loss Agents
- Weight-Loss Drugs
- Drugs, Weight-Loss
- Weight Loss Drugs
|
Below are MeSH descriptors whose meaning is more general than "Anti-Obesity Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Obesity Agents".
This graph shows the total number of publications written about "Anti-Obesity Agents" by people in this website by year, and whether "Anti-Obesity Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 4 | 6 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 0 | 4 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Obesity Agents" by people in Profiles.
-
Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program. Popul Health Manag. 2023 02; 26(1):72-82.
-
Pharmacologic Weight Management in the Era of Adolescent Obesity. J Clin Endocrinol Metab. 2022 09 28; 107(10):2716-2728.
-
Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study. J Manag Care Spec Pharm. 2022 Oct; 28(10):1066-1079.
-
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association. Hypertension. 2021 11; 78(5):e38-e50.
-
Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. J Clin Endocrinol Metab. 2021 06 16; 106(7):2103-2113.
-
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 04 13; 325(14):1403-1413.
-
Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee. J Card Fail. 2019 May; 25(5):380-400.
-
Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy. Obesity (Silver Spring). 2018 02; 26(2):332-339.
-
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017 11; 19(11):1529-1536.
-
Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017 05; 25(5):857-865.